ECOG-ACRIN Operations Center

ECOG-ACRIN 运营中心

• 批准号: 8925959
• 负责人: ROBERT L COMIS
• 金额: $ 25.98万
• 依托单位: ECOG-ACRIN MEDICAL RESEARCH FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-29 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8925959
• 关键词: Adult; American College of Radiology Imaging Network; Bioinformatics; Biological Markers; Biometry; Cancer Biology; Cancer Center; Cancer Patient; Caring; Center for Translational Science Activities; Clinical; Clinical Data; Clinical Informatics; Clinical Research; Clinical Trials; Clinical Trials Network; Collaborations; Communities; Coupled; Dana-Farber Cancer Institute; Data; Databases; Development; Diagnostic; Diagnostic Imaging; Discipline; Early Diagnosis; Eastern Cooperative Oncology Group; Extramural Activities; Fostering; Funding; Goals; Image; Information Technology; Institute of Medicine (U.S.); Institution; Intervention; Investigation; Joints; Laboratories; Leadership; Malignant Neoplasms; Minority; Molecular; Monitor; National Cancer Institute; Outcome; Patient advocacy; Patients; Phase; Population; Positioning Attribute; Public Health; Rare Diseases; Reporting; Research; Research Infrastructure; Research Personnel; Resources; Risk; Science; Shapes; Specialized Program of Research Excellence; Specimen; Subgroup; System; Tissues; Translating; Translational Research; Translations; Universities; Validation; Work; advanced disease; anticancer research; base; bench to bedside; biobank; cancer care; cancer therapy; cancer type; career development; clinical care; clinical practice; comparative effectiveness; data management; design; effectiveness research; experience; imaging modality; improved; member; multimodality; named group; operation; programs; response; scientific organization; standard of care; treatment effect

DESCRIPTION (provided by applicant): Clinical trials continue to be a cornerstone to the effort to advance care and improve outcomes for cancer patients. ECOG and ACRIN collectively have over 65 years of experience conducting high impact clinical trials that have helped shaped clinical practice. In response to the National Clinical Trials Network (NCTN) initiative, ECOG and ACRIN have merged their complementary scientific programs to form the ECOG-ACRIN Cancer Research Group (E-A). We propose a program focused on the efficient development and implementation of practice-changing science along the cancer care continuum from early detection through treatment of advanced disease. We take advantage of combined expertise in imaging, cancer biology and therapy within our scientific organization, working closely with the biostatistics and data management center at the Dana Farber Cancer Institute and Brown University, to propose a portfolio of treatment and advance imaging trials that recognize the importance of biomarkers to identify appropriate patient subgroups for precisely targeted intervention. The E-A biorepositories, image database and associated translational science centers will leverage the data collected in the context of trials to perform correlative science studies that advance our understanding of cancer biology and treatment effect. We continue to seamlessly integrate with Cancer Center and SPORE research programs to create an interface for translating NCI-supported science into clinical trials and to attract junior investigators intothe NCTN. We propose to continue collaborating across the NCTN, contributing high quality trials, leadership in advance imaging, joint trial development and important NCTN operational infrastructure. E-A will leverage unique clinical informatics expertise to contribute a data warehouse of annotated images and specimens, laboratory analytics and clinical data to foster scientific discovery. E-A will contribute an accrual network of 37 main member institutions, 200 affiliates, 36 CCOPs and minority-based CCOPs that have accrued 33750 patients to clinical trials over the last 6 years. E-A is positioned to make unique contributions to the NCTN, working to translate NCI-supported science into improved outcomes for cancer patients. RELEVANCE: The primary goal of ECOG-ACRIN is to provide the support necessary to conduct relevant and rigorous clinical trials, which benefit public health by improving the quality and standard of care for cancer patients.

描述（由申请人提供）：临床试验仍然是推进癌症患者护理和改善预后的基石。ECOG和ACRIN共同拥有超过65年的经验，进行了高影响力的临床试验，帮助塑造了临床实践。为了响应国家临床试验网络（NCTN）的倡议，ECOG和ACRIN合并了其互补的科学计划，形成了ECOG-ACRIN癌症研究组（E-A）。我们提出了一个计划，重点是有效的开发和实施实践改变科学沿着癌症护理连续体从早期发现到晚期疾病的治疗。我们利用我们科学组织内成像，癌症生物学和治疗方面的综合专业知识，与Dana Farber癌症研究所和布朗大学的生物统计学和数据管理中心密切合作，提出一系列治疗和先进的成像试验，这些试验认识到生物标志物的重要性，以确定适当的患者亚组进行精确的靶向干预。E-A生物储存库、图像数据库和相关的转化科学中心将利用在试验中收集的数据进行相关的科学研究，以促进我们对癌症生物学和治疗效果的理解。我们继续与癌症中心和SPORE研究项目无缝整合，为将NCI支持的科学转化为临床试验创造一个接口，并吸引初级研究人员进入NCTN。我们建议继续在NCTN内开展合作，提供高质量的试验，在先进成像、联合试验开发和重要的NCTN运营基础设施方面发挥领导作用。E-A将利用独特的临床信息学专业知识，为注释图像和标本、实验室分析和临床数据提供数据仓库，以促进科学发现。E-A将贡献一个由37个主要成员机构、200个附属机构、36个CCOP和少数民族CCOP组成的应计网络，在过去6年中，该网络已累计33750名患者参加临床试验。E-A的定位是为NCTN做出独特的贡献，致力于将NCI支持的科学转化为改善癌症患者的预后。 相关性：ECOG-ACRIN的主要目标是为开展相关和严格的临床试验提供必要的支持，通过提高质量来造福公众健康。 和癌症患者的护理标准。